Elisabeth von Guggenberg - Search Results

Year	Number of Results
2003	1
2004	3
2005	1
2006	2
2007	2
2008	1
2009	3
2010	3
2011	6
2012	4
2013	3
2015	2
2016	3
2017	6
2018	6
2019	6
2020	8
2021	8
2022	2
2023	5
2024	0

1

Automated production of [⁶⁸Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.

Kraihammer M, von Guggenberg E, Hörmann AA, Gabriel M, Decristoforo C. Kraihammer M, et al. Among authors: von guggenberg e. Nucl Med Biol. 2023 Sep-Oct;124-125:108381. doi: 10.1016/j.nucmedbio.2023.108381. Epub 2023 Aug 18. Nucl Med Biol. 2023. PMID: 37634398

2

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, Castel H, Gandolfo P, von Guggenberg E. Zavvar TS, et al. Among authors: von guggenberg e. Pharmaceuticals (Basel). 2023 Feb 13;16(2):278. doi: 10.3390/ph16020278. Pharmaceuticals (Basel). 2023. PMID: 37052226 Free PMC article.

3

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of ¹⁷⁷Lu-Labeled Peptide Analogs Targeting CCK2R.

Hörmann AA, Klingler M, Rangger C, Mair C, Joosten L, Franssen GM, Laverman P, von Guggenberg E. Hörmann AA, et al. Among authors: von guggenberg e. Pharmaceutics. 2023 Feb 28;15(3):796. doi: 10.3390/pharmaceutics15030796. Pharmaceutics. 2023. PMID: 36986657 Free PMC article.

4

Improved quality control of [¹⁷⁷Lu]Lu-PSMA I&T.

Kraihammer M, Garnuszek P, Bauman A, Maurin M, Alejandre Lafont M, Haubner R, von Guggenberg E, Gabriel M, Decristoforo C. Kraihammer M, et al. Among authors: von guggenberg e. EJNMMI Radiopharm Chem. 2023 Mar 27;8(1):7. doi: 10.1186/s41181-023-00191-6. EJNMMI Radiopharm Chem. 2023. PMID: 36971890 Free PMC article.

5

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the ⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.

von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, di Santo G, Virgolini IJ. von Guggenberg E, et al. J Nucl Med. 2023 Jun;64(6):859-862. doi: 10.2967/jnumed.122.264977. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657979

6

Primary small cell carcinoma of the prostate: Promising implication for double tracer PET imaging using PSMA and SSTR-ligands.

Svirydenka H, Uprimny C, Nilica B, von Guggenberg E, Rossetti LM, Virgolini I. Svirydenka H, et al. Among authors: von guggenberg e. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41 Suppl 1:S26-S28. doi: 10.1016/j.remnie.2021.04.011. Epub 2021 Apr 20. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35870839 No abstract available.

7

Automated Synthesis of ⁶⁸Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Hörmann AA, Plhak E, Klingler M, Rangger C, Pfister J, Schwach G, Kvaternik H, von Guggenberg E. Hörmann AA, et al. Among authors: von guggenberg e. Molecules. 2022 Mar 21;27(6):2034. doi: 10.3390/molecules27062034. Molecules. 2022. PMID: 35335396 Free PMC article.

8

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.

von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. von Guggenberg E, et al. Cancers (Basel). 2021 Nov 18;13(22):5776. doi: 10.3390/cancers13225776. Cancers (Basel). 2021. PMID: 34830930 Free PMC article. Review.

9

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

Bayerschmidt S, Uprimny C, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Bayerschmidt S, et al. Among authors: von guggenberg e. Diagnostics (Basel). 2021 Jun 30;11(7):1191. doi: 10.3390/diagnostics11071191. Diagnostics (Basel). 2021. PMID: 34208989 Free PMC article.

10

Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E. Hörmann AA, et al. Among authors: von guggenberg e. Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575. Pharmaceuticals (Basel). 2021. PMID: 34208516 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

65 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year